4JQX image
Deposition Date 2013-03-20
Release Date 2013-06-26
Last Version Date 2024-11-20
Entry Detail
PDB ID:
4JQX
Keywords:
Title:
HLA-B*44:03 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 169-180)
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:HLA class I histocompatibility antigen, B-44 alpha chain
Chain IDs:A
Chain Length:278
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Trans-activator protein BZLF1
Gene (Uniprot):BZLF1
Chain IDs:C (auth: B)
Chain Length:12
Number of Molecules:1
Biological Source:Human herpesvirus 4
Polymer Type:polypeptide(L)
Molecule:Beta-2-microglobulin
Gene (Uniprot):B2M
Chain IDs:B (auth: C)
Chain Length:99
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
HLA Peptide Length Preferences Control CD8+ T Cell Responses.
J.Immunol. 191 561 571 (2013)
PMID: 23749632 DOI: 10.4049/jimmunol.1300292

Abstact

Class I HLAs generally present peptides of 8-10 aa in length, although it is unclear whether peptide length preferences are affected by HLA polymorphism. In this study, we investigated the CD8(+) T cell response to the BZLF1 Ag of EBV, which includes overlapping sequences of different size that nevertheless conform to the binding motif of the large and abundant HLA-B*44 supertype. Whereas HLA-B*18:01(+) individuals responded strongly and exclusively to the octamer peptide (173)SELEIKRY(180), HLA-B*44:03(+) individuals responded to the atypically large dodecamer peptide (169)EECDSELEIKRY(180), which encompasses the octamer peptide. Moreover, the octamer peptide bound more stably to HLA-B*18:01 than did the dodecamer peptide, whereas, conversely, HLA-B*44:03 bound only the longer peptide. Furthermore, crystal structures of these viral peptide-HLA complexes showed that the Ag-binding cleft of HLA-B*18:01 was more ideally suited to bind shorter peptides, whereas HLA-B*44:03 exhibited characteristics that favored the presentation of longer peptides. Mass spectrometric identification of > 1000 naturally presented ligands revealed that HLA-B*18:01 was more biased toward presenting shorter peptides than was HLA-B*44:03. Collectively, these data highlight a mechanism through which polymorphism within an HLA class I supertype can diversify determinant selection and immune responses by varying peptide length preferences.

Legend

Protein

Chemical

Disease

Primary Citation of related structures